ClinicalTrials.gg
CompletedNCT01009814Updated Jan 3, 2020Results posted

Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1

A Phase 2 interventional study of BMS-663068 and Ritonavir in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-03.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
128th of 210
50 · median 82
Started
2009
with 8 others
Phase 2
48 of 266
2 open now
Registered
132nd of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 128th largest by enrollment of the 210 interventional ones that give a count, is one of 9 that started in 2009, is one of 48 in phase 2, and was the 132nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

Research Hypothesis: Administration of BMS-663068, a prodrug for HIV attachment inhibitor BMS-626529, will result in a mean decrease of at least 1 log10 in HIV RNA at Day 9 following 8 days of therapy in at least one dosing regimen that is safe and well tolerated in Clade B HIV-1 infected subjects.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV, HIV attachment inhibitor, attachment inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clade B -1 infected subjects meeting following criteria at screening:

    • Plasma HIV RNA ≥ 5,000 copies/mL
    • CD4+ lymphocyte ≥ 200 cells/µL
    • Antiretroviral naive or experienced
    • Off all ARV therapy with HIV activity for > 8 weeks
  • of 18 to 35 kg/m2, inclusive.
  • Not currently co-infected with or
  • Men and women, ≥ 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Woman of (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period up to 12 weeks after the last dose of study drug.
  • WOCBP using prohibited method including oral, injectable, or implantable hormonal contraceptive agent within 12 weeks of enrollment.
  • Women who are pregnant or breastfeeding.
  • Women with positive pregnancy test on enrollment or prior to study drug intake.
  • Sexually active fertile men not using effective birth control during study and for at least 12 weeks after last dose of study drug if partners are WOCBP.
  • Significant acute or chronic medical illness not stable or not controlled with medication or not consistent with infection.
  • Current or recent (within 3 months) gastrointestinal disease that, in the opinion of Investigator or Medical Monitor, may impact on drug absorption and/or put subject at risk for GI tract irritation and/or bleeding.
  • Acute diarrhea lasting ≥ 1 day, within 3 weeks prior to randomization.
  • Major surgery within 4 weeks of study drug intake.
  • Gastrointestinal surgery that could impact upon absorption of study drug.
  • Donation of blood or plasma to blood bank or in a clinical study (except a Screening visit or follow up visit of less than 50 mL) within 4 weeks of study drug intake.
  • Blood transfusion within 4 weeks of study drug intake.
  • Inability to tolerate oral medication.
  • Inability to be venipunctured and/or tolerate venous access.
  • Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades de pointes.
  • Personal or family history of long syndrome.
  • Recent (within 6 months) drug/alcohol abuse
  • Any other medical, psychiatric and/or social reason which, in the opinion of the Investigator, would make the candidate inappropriate for participation.
  • Evidence of organ dysfunction or clinically significant deviation from normal in physical examination, vital signs, or clinical lab determinations or not consistent with subject's degree of HIV infection.
  • Evidence of 2nd or 3rd degree heart block at screening or Day -1
  • Positive urine drug screen at Screening or Day -1 without valid prescription (subjects positive for cannabinoids and/or amphetamines will be included).
  • Positive blood screen for surface antigen.
  • Positive blood screen for antibody and hepatitis C RNA.
  • History of significant drug allergy
  • Exposure to any drug or placebo within 4 weeks of study drug intake.
  • Prescription drugs within 4 weeks prior to study drug intake, unless approved by BMS medical monitor.
  • Other drugs, including over-the-counter medications, vitamins and/or herbal preparations, within 1 week prior to study drug intake, unless approved by BMS medical monitor.
  • Use of oral, injectable or implantable hormonal contraceptive agent within 12 weeks of study drug intake.
  • Use of prescription drugs or OTC drugs that may cause GI tract irritation or bleeding within 2 weeks of study drug intake, unless approved by BMS medical monitor.
  • Use of alcohol-containing beverages within 3 days prior to study drug intake.
  • Use of grapefruit, grapefruit-containing or Seville orange-containing products within 7 days prior to study drug intake.
  • Prisoners or subjects involuntarily incarcerated.
  • Subjects compulsorily detained for treatment of either a psychiatric or physical illness.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    BMS-663068 600 mg Q12H + RTV 100 mg Q12H

    All participants received BMS-663068 600 milligram (mg) and Ritonavir (RTV) 100 mg every 12 hours (Q12H) from Day 1 to Day 8.

    Drug: BMS-663068 · Drug: Ritonavir

  • Experimental
    BMS-663068 1200 mg QHS + RTV 100 mg QHS

    All participants received BMS-663068 1200 mg and RTV 100 mg every night (quaque hora somni \[QHS\]) from Day 1 to Day 8.

    Drug: BMS-663068 · Drug: Ritonavir

  • Experimental
    BMS-663068 1200 mg Q12H + RTV 100 mg Q12H

    All participants received BMS-663068 1200 mg and RTV 100 mg Q12H from Day 1 to Day 8.

    Drug: BMS-663068 · Drug: Ritonavir

  • Experimental
    BMS-663068 1200 mg Q12H + RTV 100 mg QAM

    All participants received BMS-663068 1200 mg Q12H and RTV 100 mg every 24 hours in the morning (quaque ante meridiem \[QAM\]) from Day 1 to Day 8.

    Drug: BMS-663068 · Drug: Ritonavir

  • Experimental
    BMS-663068 1200 mg Q12H

    All participants received BMS-663068 1200 mg Q12H from Day 1 to Day 8.

    Drug: BMS-663068

Interventions

  • BMS-663068 will be administered as a tablet formulation

  • Ritonavir will be administered as a capsule.

06

What researchers measure

Primary outcomes

  1. Mean Logarithm With Base 10 (Log10) Change From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Day 9

    The primary assessment of the antiviral activity of BMS-663068 was assessed on the log10 change from Baseline in HIV RNA to Day 9. Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline value from post-Baseline visit value. An analysis of covariance (ANCOVA) model correcting for Baseline HIV viral load and treatment group was used to test the differences in mean log10 decrease in HIV RNA at Day 9 between 2 regimen groups by antiretroviral treatment history (ARV \[antiretroviral\] naive, ARV experienced, and combined \[ARV naive + ARV experienced\]). For the combined group (ARV naive +ARV experienced) an additional ANCOVA was used correcting also for treatment history as an additional covariate. Only Clade B participants were included in the population.

    Time frame: Baseline and Day 9

Secondary outcomes

  1. Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count and Cluster of Differentiation 8 Positive (CD8+) Cell Count

    Blood samples were collected for evaluation of CD4+ and CD8+ cells at Baseline (Day 1, pre-dose), Day 8, Day 15 (Follow up) and Day 50 (study discharge). Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline value from post-Baseline visit value.

    Time frame: Baseline (Day 1 pre-dose), Day 8, Day 15 and Day 50

  2. Change From Baseline in Percent CD4+ Cell Count and Percent CD8+ Cell Count

    Blood samples were collected for evaluation of percent CD4+ and percent CD8+ cells at Baseline (Day 1, pre-dose), Day 8, Day 15 (Follow up) and Day 50 (study discharge). Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline visit value from post-Baseline visit value.

    Time frame: Baseline (Day 1 pre-dose), Day 8, Day 15 and Day 50

  3. Number of Participants With Treatment Emergent Non-serious Adverse Event (Non-SAE) and Serious AE (SAE)

    An AE is any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Any untoward medical occurrence resulting in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent serious outcomes were categorized as SAE. Treatment emergent adverse events (occurred after start of treatment) have been presented.Safety Population comprised of all randomized participants who used the trial medication at least once.

    Time frame: Up to 50 days

  4. Number of Participants With Any Abnormality in Physical Examination

    A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. A brief physical examination included, at a minimum assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Any abnormality found by investigator during physical examination were recorded. Number of participants with any abnormality in physical examination during study have been reported.

    Time frame: Up to 50 days

  5. Number of Participants With Worst-case Abnormalities in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

    Vital signs including DBP and SBP were recorded. Normal ranges were as following: For DBP, lower limit: value \<55 millimeter of mercury (mmHg) and change \<-20 mmHg; upper limit: value \>90 mmHg and change \>20 mmHg). For SBP, lower limit: value \<90 mmHg and change \<-10 mmHg; upper limit: value \>140 mmHg and change \>10 mmHg. Number of participants with worst-case abnormalities are presented. Worst-case abnormality was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. (3) Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.

    Time frame: Up to 50 days

  6. Number of Participants With Worst-case Abnormalities in Body Temperature, Respiratory Rate [RR], and Heart Rate [HR]

    Vital signs (body temperature, RR, and HR) were recorded. Normal range were: For HR, lower limit: 55 beats per minute (bpm) and change \<-15 bpm; upper limit: \>100 bpm and change \>30 bpm). For temperature, lower limit: 36.0 Celsius; upper limit: \>37.5 Celsius or change \>1.7 Celsius). For RR, lower limit: 8 breaths per minute; upper limit: \>16 breaths per minute or change \>10 breaths per minute. Number of participants with worst-case abnormalities are presented. Worst-case abnormality was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. (3) Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.

    Time frame: Up to 50 days

  7. Number of Participants With Worst-case Abnormalities in Electrocardiogram (ECG) Parameters

    A 12-lead ECG was recorded during the study using an ECG machine that automatically measures ECG parameters. Normal range for ECG parameters were: PR interval (upper: 200 milliseconds \[ms\]); QRS (lower: 50 ms; upper: 120 ms); Corrected QT interval by Bazett formula (QTcB) (change from Baseline - increases by \> 30 ms); Corrected QT interval by Fredericia formula (QTcF) (change from Baseline - increases by \> 30 ms). Number of participants with worst-case abnormalities are presented which was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.

    Time frame: Up to 50 days

  8. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Laboratory parameters included hematology, clinical chemistry and urine parameters. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Any abnormal laboratory test results which were considered clinically significant by the investigator were recorded on the case report form. Number of participants with any clinically significant abnormalities in laboratory parameters have been presented.

    Time frame: Up to 50 days

  9. Maximum Observed Plasma Concentration (Cmax) of BMS-626529 Following Q12H Dosing

    Blood samples were collected at indicated time points to assess Cmax of BMS-626529 following Q12H dosing. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (Anti Meridiem \[AM\]), Day 8 evening dose (Post Meridiem \[PM\]) and Day 8 morning + evening dose (AM+PM). Pharmacokinetic parameter values were derived by non-compartmental methods. Pharmacokinetic (PK) Population was used which comprised of all participants who receive BMS-663068 and provided pharmacokinetic samples.

    Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours

  10. Cmax of BMS-626529 Following QHS Dosing

    Blood samples were collected at indicated time points to assess Cmax of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 evening dose (PM) and Day 8 morning (AM) + evening dose (PM).

    Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours

  11. Trough Observed Plasma Concentration (Ctrough) of BMS-626529 Following Q12H Dosing

    Blood samples were collected at indicated time points to access Ctrough of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8, Day 8 morning dose (AM) and Day 8 evening dose (PM).

    Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Days 5,6,7: pre-morning dose

  12. Ctrough of BMS-626529 Following QHS Dosing

    Blood samples were collected at indicated time points to assess Ctrough of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8 and Day 8 evening dose (PM).

    Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 5,6,7: pre-evening dose

  13. Area Under the Concentration-time Curve in One Dosing Interval (AUC [Tau]) of BMS-626529 Following Q12H Dosing

    Blood samples were collected at indicated time points to assess AUC (tau) of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM) and Day 8 evening dose (PM).

    Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours

  14. AUC (Tau) of BMS-626529 Following QHS Dosing

    Blood samples were collected at indicated time points to assess AUC (tau) of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1 and Day 8 evening dose (PM).

    Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours

  15. Area Under the Concentration-time Curve Over a 24-hour Period (AUC [0-24]) of BMS-626529 Following Q12H Dosing

    Blood samples were collected at indicated time points to assess AUC (0-24) of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.

    Time frame: Day 8: pre-morning dose, 1,2,3,4,5,6,8,12, 13,14,15,16,17,18,20 hours

  16. AUC (0-24) of BMS-626529 Following QHS Dosing

    Blood samples were collected at indicated time points to assess AUC (0-24) of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.

    Time frame: Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours

  17. Accumulation Index (AI) of BMS-626529 Following Q12H Dosing

    Blood samples were collected at indicated time points to assess Accumulation Index of BMS-626529 following Q12H dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 morning dose (AM).

    Time frame: Day 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours

  18. Accumulation Index of BMS-626529 Following QHS Dosing

    Blood samples were collected at indicated time points to assess Accumulation Index of BMS-626529 following QHS dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 evening dose (PM).

    Time frame: Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours

  19. Inhibitory Quotient (IQ) of BMS-626529 by Css,Avg and by Lowest Concentration of a Drug During Dosing Interval (Cmin) Following Q12H Dosing

    Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measures were used in evaluating IQ: Cmin and Css,avg. Geometric mean and geometric coefficient of variation are presented.

    Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Day 9: pre-dose, 4,12 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-morning dose

  20. Inhibitory Quotient (IQ) of BMS-626529 by Css,Avg and by Lowest Concentration of a Drug During Dosing Interval (Cmin) Following QHS Dosing

    Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measures were used in evaluating IQ: Cmin and Css,avg. Geometric mean and geometric coefficient of variation are presented.

    Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Day 2: pre-evening dose, 12,16 hours; Day 9: pre-dose, 12,16 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-evening dose

  21. Inhibitory Quotient of BMS-626529 by Ctrough Following Q12H Dosing

    Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measure was used in evaluating IQ: Ctrough. Geometric mean and geometric coefficient of variation are presented.

    Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Day 9: pre-dose, 4,12 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-morning dose

  22. Inhibitory Quotient of BMS-626529 by Ctrough Following QHS Dosing

    Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measure was used in evaluating IQ: Ctrough. Geometric mean and geometric coefficient of variation are presented.

    Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 2: pre-evening dose, 12,16 hours; Day 9: pre-dose, 12,16 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-evening dose

  23. Cmax of Ritonavir Following Q12H Dosing

    Blood samples were collected at indicated time points to assess Cmax of ritonavir following Q12H dosing. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM), Day 8 evening dose (PM) and Day 8 morning + evening dose (AM+PM). Pharmacokinetic parameter values were derived by non-compartmental methods. PK Population was used which comprised of all participants who receive ritonavir and provided pharmacokinetic samples.

    Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours

  24. Cmax of Ritonavir Following QHS Dosing

    Blood samples were collected at indicated time points to assess Cmax of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 evening dose (PM) and Day 8 morning (AM) + evening dose (PM).

    Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours

  25. Ctrough of Ritonavir Following Q12H Dosing

    Blood samples were collected at indicated time points to access Ctrough of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8, Day 8 morning dose (AM) and Day 8 evening dose (PM).

    Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Days 5,6,7: pre-morning dose

  26. Ctrough of Ritonavir Following QHS Dosing

    Blood samples were collected at indicated time points to assess Ctrough of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8 and Day 8 evening dose (PM).

    Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 5,6,7: pre-evening dose

  27. AUC (Tau) of Ritonavir Following Q12H Dosing

    Blood samples were collected at indicated time points to assess AUC (tau) of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM) and Day 8 evening dose (PM).

    Time frame: Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours

  28. AUC (Tau) of Ritonavir Following QHS Dosing

    Blood samples were collected at indicated time points to assess AUC (tau) of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1 and Day 8 evening dose (PM).

    Time frame: Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours

  29. AUC (0-24) of Ritonavir Following Q12H Dosing

    Blood samples were collected at indicated time points to assess AUC (0-24) of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.

    Time frame: Day 8: pre-morning dose, 1,2,3,4,5,6,8,12, 13,14,15,16,17,18,20 hours

  30. AUC (0-24) of Ritonavir Following QHS Dosing

    Blood samples were collected at indicated time points to assess AUC (0-24) of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.

    Time frame: Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours

  31. Accumulation Index of Ritonavir Following Q12H Dosing

    Blood samples were collected at indicated time points to assess Accumulation Index of ritonavir following Q12H dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 morning dose (AM).

    Time frame: Day 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours

  32. Accumulation Index of Ritonavir Following QHS Dosing

    Blood samples were collected at indicated time points to assess Accumulation Index of ritonavir following QHS dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 evening dose (PM).

    Time frame: Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours

07

Results

Posted Jan 3, 2020

Participant flow

This was a randomized, open label, multiple-dose study to evaluate the pharmacodynamics, safety and pharmacokinetics of BMS-663068 in human immunodeficiency virus 1 (HIV-1) infected participants. The study was conducted at single center in Germany.

Participant flow — Overall Study
MilestoneBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Started1010101010
Completed99101010
Not completed11000
Withdrew: No longer met study criteria11000

Outcome measures

PrimaryMean Logarithm With Base 10 (Log10) Change From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Day 9

The primary assessment of the antiviral activity of BMS-663068 was assessed on the log10 change from Baseline in HIV RNA to Day 9. Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline value from post-Baseline visit value. An analysis of covariance (ANCOVA) model correcting for Baseline HIV viral load and treatment group was used to test the differences in mean log10 decrease in HIV RNA at Day 9 between 2 regimen groups by antiretroviral treatment history (ARV \[antiretroviral\] naive, ARV experienced, and combined \[ARV naive + ARV experienced\]). For the combined group (ARV naive +ARV experienced) an additional ANCOVA was used correcting also for treatment history as an additional covariate. Only Clade B participants were included in the population.

Time frame:
Baseline and Day 9
Reported as:
Mean · Log10 copies per milliliter (c/mL)
Mean Logarithm With Base 10 (Log10) Change From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Day 9
Log10 copies per milliliter (c/mL)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Mean Logarithm With Base 10 (Log10) Change From Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Day 9-1.3445 ± 0.07925-1.2532 ± 0.10610-1.2381 ± 0.10455-1.1888 ± 0.12938-0.8760 ± 0.22621
Statistical analysis
  • BMS-663068 600 mg Q12H + RTV 100 mg Q12H vs BMS-663068 1200 mg QHS + RTV 100 mg QHS · ANCOVA · p = 0.6102 · Mean difference (net): -0.1089 · 90% CI -0.4656 to 0.2477
  • BMS-663068 600 mg Q12H + RTV 100 mg Q12H vs BMS-663068 1200 mg Q12H + RTV 100 mg Q12H · ANCOVA · p = 0.5452 · Mean difference (net): -0.1266 · 90% CI -0.4758 to 0.2225
  • BMS-663068 600 mg Q12H + RTV 100 mg Q12H vs BMS-663068 1200 mg Q12H + RTV 100 mg QAM · ANCOVA · p = 0.4178 · Mean difference (net): -0.1682 · 90% CI -0.5139 to 0.1775
  • BMS-663068 600 mg Q12H + RTV 100 mg Q12H vs BMS-663068 1200 mg Q12H · ANCOVA · p = 0.0233 · Mean difference (net): -0.4885 · 90% CI -0.8375 to -0.1395
  • BMS-663068 1200 mg QHS + RTV 100 mg QHS vs BMS-663068 1200 mg Q12H + RTV 100 mg Q12H · ANCOVA · p = 0.9314 · Mean difference (net): -0.0177 · 90% CI -0.3613 to 0.3259
  • BMS-663068 1200 mg QHS + RTV 100 mg QHS vs BMS-663068 1200 mg Q12H + RTV 100 mg QAM · ANCOVA · p = 0.7734 · Mean difference (net): -0.0592 · 90% CI -0.4032 to 0.2847
  • BMS-663068 1200 mg QHS + RTV 100 mg QHS vs BMS-663068 1200 mg Q12H · ANCOVA · p = 0.0702 · Mean difference (net): -0.3796 · 90% CI -0.7232 to -0.0360
  • BMS-663068 1200 mg Q12H + RTV 100 mg Q12H vs BMS-663068 1200 mg Q12H + RTV 100 mg QAM · ANCOVA · p = 0.8359 · Mean difference (net): -0.0415 · 90% CI -0.3768 to 0.2937
  • BMS-663068 1200 mg Q12H + RTV 100 mg Q12H vs BMS-663068 1200 mg Q12H · ANCOVA · p = 0.0759 · Mean difference (net): -0.3619 · 90% CI -0.6962 to -0.0275
  • BMS-663068 1200 mg Q12H + RTV 100 mg QAM vs BMS-663068 1200 mg Q12H · ANCOVA · p = 0.1155 · Mean difference (net): -0.3203 · 90% CI -0.6555 to 0.0149
SecondaryChange From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count and Cluster of Differentiation 8 Positive (CD8+) Cell Count

Blood samples were collected for evaluation of CD4+ and CD8+ cells at Baseline (Day 1, pre-dose), Day 8, Day 15 (Follow up) and Day 50 (study discharge). Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline value from post-Baseline visit value.

Time frame:
Baseline (Day 1 pre-dose), Day 8, Day 15 and Day 50
Reported as:
Mean · Cells per microliter (cells/μL)
Change From Baseline in Cluster of Differentiation 4 Positive (CD4+) Cell Count and Cluster of Differentiation 8 Positive (CD8+) Cell Count
Cells per microliter (cells/μL)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
CD4+, Day 8, n=9, 9, 10, 10, 10114.2 ± 74.5593.4 ± 25.12109.8 ± 32.3738.5 ± 41.6132.0 ± 36.23
CD4+, Day 15, n=9, 9, 10, 10, 1058.4 ± 92.14-6.1 ± 28.15117.6 ± 27.6744.6 ± 69.9410.4 ± 23.38
CD4+, Day 50, n=9, 9, 10, 10, 922.0 ± 91.55-50.3 ± 18.0671.1 ± 28.55-48.4 ± 61.21-19.2 ± 17.05
CD8+, Day 8, n=9, 9, 10, 10, 10384.2 ± 164.35189.0 ± 134.27218.4 ± 125.65114.9 ± 131.6494.6 ± 152.73
CD8+, Day 15, n=9, 9, 10, 10, 1064.8 ± 230.86-153.2 ± 137.1885.6 ± 112.65-99.6 ± 159.83-4.4 ± 126.77
CD8+, Day 50, n=9, 9, 10, 10, 9-37.6 ± 161.11-292.4 ± 121.73139.7 ± 95.006.0 ± 170.29-48.2 ± 140.55
SecondaryChange From Baseline in Percent CD4+ Cell Count and Percent CD8+ Cell Count

Blood samples were collected for evaluation of percent CD4+ and percent CD8+ cells at Baseline (Day 1, pre-dose), Day 8, Day 15 (Follow up) and Day 50 (study discharge). Baseline was the last non-missing observation before first dose (Day 1 pre-dose) and change from Baseline was calculated by subtracting Baseline visit value from post-Baseline visit value.

Time frame:
Baseline (Day 1 pre-dose), Day 8, Day 15 and Day 50
Reported as:
Mean · Percent cells per microliter
Change From Baseline in Percent CD4+ Cell Count and Percent CD8+ Cell Count
Percent cells per microliterBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Percent CD4+, Day 8, n=9, 9, 10, 10, 10-1.0 ± 1.121.2 ± 0.970.6 ± 0.780.1 ± 0.721.4 ± 1.11
Percent CD4+, Day 15, n=9, 9, 10, 10, 101.6 ± 1.001.2 ± 0.641.4 ± 1.332.4 ± 1.110.9 ± 1.51
Percent CD4+, Day 50, n=9, 9, 10, 10, 91.4 ± 0.841.1 ± 1.150.3 ± 0.90-1.7 ± 0.970.6 ± 1.45
Percent CD8+, Day 8, n=9, 9, 10, 10, 101.0 ± 0.76-0.4 ± 1.020.1 ± 1.06-0.3 ± 1.11-0.2 ± 1.20
Percent CD8+, Day 15, n=9, 9, 10, 10, 10-3.4 ± 0.73-2.8 ± 1.00-2.9 ± 1.49-4.0 ± 1.73-2.9 ± 1.16
Percent CD8+, Day 50, n=9, 9, 10, 10, 9-2.2 ± 1.01-0.7 ± 1.22-0.9 ± 1.191.6 ± 1.52-2.4 ± 1.57
SecondaryNumber of Participants With Treatment Emergent Non-serious Adverse Event (Non-SAE) and Serious AE (SAE)

An AE is any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Any untoward medical occurrence resulting in death, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent serious outcomes were categorized as SAE. Treatment emergent adverse events (occurred after start of treatment) have been presented.Safety Population comprised of all randomized participants who used the trial medication at least once.

Time frame:
Up to 50 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Non-serious Adverse Event (Non-SAE) and Serious AE (SAE)
ParticipantsBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Non-SAE85989
SAE00000
SecondaryNumber of Participants With Any Abnormality in Physical Examination

A complete physical examination included, at a minimum, assessment of the Cardiovascular, Respiratory, Gastrointestinal and Neurological systems. A brief physical examination included, at a minimum assessments of the skin, lungs, cardiovascular system, and abdomen (liver and spleen). Any abnormality found by investigator during physical examination were recorded. Number of participants with any abnormality in physical examination during study have been reported.

Time frame:
Up to 50 days
Reported as:
Count of participants · Participants
Number of Participants With Any Abnormality in Physical Examination
ParticipantsBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Number of Participants With Any Abnormality in Physical Examination10211
SecondaryNumber of Participants With Worst-case Abnormalities in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)

Vital signs including DBP and SBP were recorded. Normal ranges were as following: For DBP, lower limit: value \<55 millimeter of mercury (mmHg) and change \<-20 mmHg; upper limit: value \>90 mmHg and change \>20 mmHg). For SBP, lower limit: value \<90 mmHg and change \<-10 mmHg; upper limit: value \>140 mmHg and change \>10 mmHg. Number of participants with worst-case abnormalities are presented. Worst-case abnormality was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. (3) Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.

Time frame:
Up to 50 days
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Abnormalities in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
ParticipantsBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
SBP, Above Normal03101
SBP, Below Normal00000
SBP, Within Normal1079109
DBP, Above Normal00000
DBP, Below Normal00000
DBP, Within Normal1010101010
SecondaryNumber of Participants With Worst-case Abnormalities in Body Temperature, Respiratory Rate [RR], and Heart Rate [HR]

Vital signs (body temperature, RR, and HR) were recorded. Normal range were: For HR, lower limit: 55 beats per minute (bpm) and change \<-15 bpm; upper limit: \>100 bpm and change \>30 bpm). For temperature, lower limit: 36.0 Celsius; upper limit: \>37.5 Celsius or change \>1.7 Celsius). For RR, lower limit: 8 breaths per minute; upper limit: \>16 breaths per minute or change \>10 breaths per minute. Number of participants with worst-case abnormalities are presented. Worst-case abnormality was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. (3) Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.

Time frame:
Up to 50 days
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Abnormalities in Body Temperature, Respiratory Rate [RR], and Heart Rate [HR]
ParticipantsBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
HR, Above Normal00000
HR, Below Normal12101
HR, Within Normal989109
RR, Above Normal43338
RR, Below Normal00000
RR, Within Normal67772
Temperature, Above Normal00000
Temperature, Below Normal12010
Temperature, Within Normal9810910
SecondaryNumber of Participants With Worst-case Abnormalities in Electrocardiogram (ECG) Parameters

A 12-lead ECG was recorded during the study using an ECG machine that automatically measures ECG parameters. Normal range for ECG parameters were: PR interval (upper: 200 milliseconds \[ms\]); QRS (lower: 50 ms; upper: 120 ms); Corrected QT interval by Bazett formula (QTcB) (change from Baseline - increases by \> 30 ms); Corrected QT interval by Fredericia formula (QTcF) (change from Baseline - increases by \> 30 ms). Number of participants with worst-case abnormalities are presented which was defined as: (1) Below Normal: at least one post-Baseline assessment was below normal range, and no post-Baseline assessment was above normal range. (2) Above Normal: at least one post-Baseline assessment was above normal range, and no post-Baseline assessment was below normal range. Within Normal: all post-Baseline assessments were within normal range. It was to be considered as 'Missing' when there were no post-Baseline assessments.

Time frame:
Up to 50 days
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Abnormalities in Electrocardiogram (ECG) Parameters
ParticipantsBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
PR interval, Above Normal01001
PR interval, Below Normal00000
PR interval, Within Normal10910109
QTcB, Above Normal01201
QTcB, Below Normal00000
QTcB, Within Normal1098109
QTcF, Above Normal10102
QTcF, Below Normal00000
QTcF, Within Normal9109108
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Laboratory parameters included hematology, clinical chemistry and urine parameters. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Any abnormal laboratory test results which were considered clinically significant by the investigator were recorded on the case report form. Number of participants with any clinically significant abnormalities in laboratory parameters have been presented.

Time frame:
Up to 50 days
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters00000
SecondaryMaximum Observed Plasma Concentration (Cmax) of BMS-626529 Following Q12H Dosing

Blood samples were collected at indicated time points to assess Cmax of BMS-626529 following Q12H dosing. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (Anti Meridiem \[AM\]), Day 8 evening dose (Post Meridiem \[PM\]) and Day 8 morning + evening dose (AM+PM). Pharmacokinetic parameter values were derived by non-compartmental methods. Pharmacokinetic (PK) Population was used which comprised of all participants who receive BMS-663068 and provided pharmacokinetic samples.

Time frame:
Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Reported as:
Geometric mean · Micrograms per milliliter (μg/mL)
Maximum Observed Plasma Concentration (Cmax) of BMS-626529 Following Q12H Dosing
Micrograms per milliliter (μg/mL)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Day 1, n=10,10,10,101.74 ± 59.93.52 ± 26.64.05 ± 35.82.55 ± 27.4
Day 8, AM, n=9,10,10,102.22 ± 67.15.55 ± 37.55.10 ± 57.43.18 ± 22.0
Day 8, PM, n=9,10,10,102.25 ± 46.44.60 ± 29.24.77 ± 36.23.61 ± 27.5
Day 8, AM+PM, n=9,10,10,102.24 ± 43.35.05 ± 31.74.93 ± 40.13.39 ± 15.9
SecondaryCmax of BMS-626529 Following QHS Dosing

Blood samples were collected at indicated time points to assess Cmax of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 evening dose (PM) and Day 8 morning (AM) + evening dose (PM).

Time frame:
Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Reported as:
Geometric mean · μg/mL
Cmax of BMS-626529 Following QHS Dosing
μg/mLBMS-663068 1200 mg QHS + RTV 100 mg QHS
Day 1, n=103.85 ± 32.0
Day 8, PM, n=93.47 ± 31.7
Day 8, AM+PM, n=93.47 ± 31.7
SecondaryTrough Observed Plasma Concentration (Ctrough) of BMS-626529 Following Q12H Dosing

Blood samples were collected at indicated time points to access Ctrough of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8, Day 8 morning dose (AM) and Day 8 evening dose (PM).

Time frame:
Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Days 5,6,7: pre-morning dose
Reported as:
Geometric mean · Micrograms per milliliter (μg/mL)
Trough Observed Plasma Concentration (Ctrough) of BMS-626529 Following Q12H Dosing
Micrograms per milliliter (μg/mL)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Day 1, n=10,10,10,100.349 ± 1560.499 ± 83.40.640 ± 1140.244 ± 78.3
Day 5, n=9,10,10,100.473 ± 1191.04 ± 72.20.760 ± 67.10.518 ± 48.2
Day 6, n=9,10,10,100.436 ± 89.50.839 ± 49.10.737 ± 73.20.451 ± 49.2
Day 7, n=9,10,10,100.495 ± 96.51.08 ± 72.90.998 ± 91.80.542 ± 73.5
Day 8, n=9,10,10,100.460 ± 89.20.743 ± 47.10.720 ± 83.50.628 ± 76.9
Day 8, AM, n=9,10,10,100.422 ± 69.10.951 ± 88.20.579 ± 71.50.469 ± 122
Day 8, PM, n=9,10,10,100.358 ± 1020.653 ± 1090.553 ± 68.10.487 ± 47.5
SecondaryCtrough of BMS-626529 Following QHS Dosing

Blood samples were collected at indicated time points to assess Ctrough of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8 and Day 8 evening dose (PM).

Time frame:
Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 5,6,7: pre-evening dose
Reported as:
Geometric mean · μg/mL
Ctrough of BMS-626529 Following QHS Dosing
μg/mLBMS-663068 1200 mg QHS + RTV 100 mg QHS
Day 1, n=100.699 ± 93.4
Day 5, n=90.0705 ± 114
Day 6, n=90.0743 ± 97.7
Day 7, n=90.0719 ± 166
Day 8, n=90.0546 ± 146
Day 8, PM, n=90.0544 ± 156
SecondaryArea Under the Concentration-time Curve in One Dosing Interval (AUC [Tau]) of BMS-626529 Following Q12H Dosing

Blood samples were collected at indicated time points to assess AUC (tau) of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM) and Day 8 evening dose (PM).

Time frame:
Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Reported as:
Geometric mean · Hour*micrograms per milliliter
Area Under the Concentration-time Curve in One Dosing Interval (AUC [Tau]) of BMS-626529 Following Q12H Dosing
Hour*micrograms per milliliterBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Day 1, n=10,10,10,109.16 ± 68.718.3 ± 28.820.6 ± 45.013.8 ± 28.3
Day 8, AM, n=9,10,10,1013.1 ± 62.729.9 ± 37.027.6 ± 48.419.5 ± 20.5
Day 8, PM, n=9,10,10,1013.1 ± 63.830.6 ± 26.327.0 ± 45.222.5 ± 34.0
SecondaryAUC (Tau) of BMS-626529 Following QHS Dosing

Blood samples were collected at indicated time points to assess AUC (tau) of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1 and Day 8 evening dose (PM).

Time frame:
Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Reported as:
Geometric mean · Hour*micrograms per milliliter
AUC (Tau) of BMS-626529 Following QHS Dosing
Hour*micrograms per milliliterBMS-663068 1200 mg QHS + RTV 100 mg QHS
Day 1, n=1025.5 ± 38.0
Day 8 PM, n=923.0 ± 48.2
SecondaryArea Under the Concentration-time Curve Over a 24-hour Period (AUC [0-24]) of BMS-626529 Following Q12H Dosing

Blood samples were collected at indicated time points to assess AUC (0-24) of BMS-626529 following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.

Time frame:
Day 8: pre-morning dose, 1,2,3,4,5,6,8,12, 13,14,15,16,17,18,20 hours
Reported as:
Geometric mean · Hour*micrograms per milliliter
Area Under the Concentration-time Curve Over a 24-hour Period (AUC [0-24]) of BMS-626529 Following Q12H Dosing
Hour*micrograms per milliliterBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Area Under the Concentration-time Curve Over a 24-hour Period (AUC [0-24]) of BMS-626529 Following Q12H Dosing26.8 ± 56.160.6 ± 30.655.1 ± 44.342.6 ± 21.5
SecondaryAUC (0-24) of BMS-626529 Following QHS Dosing

Blood samples were collected at indicated time points to assess AUC (0-24) of BMS-626529 following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.

Time frame:
Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Reported as:
Geometric mean · Hour*micrograms per milliliter
AUC (0-24) of BMS-626529 Following QHS Dosing
Hour*micrograms per milliliterBMS-663068 1200 mg QHS + RTV 100 mg QHS
AUC (0-24) of BMS-626529 Following QHS Dosing23.0 ± 48.2
SecondaryAccumulation Index (AI) of BMS-626529 Following Q12H Dosing

Blood samples were collected at indicated time points to assess Accumulation Index of BMS-626529 following Q12H dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 morning dose (AM).

Time frame:
Day 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Reported as:
Geometric mean · Ratio of AUC
Accumulation Index (AI) of BMS-626529 Following Q12H Dosing
Ratio of AUCBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Accumulation Index (AI) of BMS-626529 Following Q12H Dosing1.53 ± 49.41.63 ± 26.71.34 ± 25.41.42 ± 37.0
SecondaryAccumulation Index of BMS-626529 Following QHS Dosing

Blood samples were collected at indicated time points to assess Accumulation Index of BMS-626529 following QHS dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 evening dose (PM).

Time frame:
Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Reported as:
Geometric mean · Ratio of AUC
Accumulation Index of BMS-626529 Following QHS Dosing
Ratio of AUCBMS-663068 1200 mg QHS + RTV 100 mg QHS
Accumulation Index of BMS-626529 Following QHS Dosing0.912 ± 27.1
SecondaryInhibitory Quotient (IQ) of BMS-626529 by Css,Avg and by Lowest Concentration of a Drug During Dosing Interval (Cmin) Following Q12H Dosing

Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measures were used in evaluating IQ: Cmin and Css,avg. Geometric mean and geometric coefficient of variation are presented.

Time frame:
Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Day 9: pre-dose, 4,12 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-morning dose
Reported as:
Geometric mean · Ratio
Inhibitory Quotient (IQ) of BMS-626529 by Css,Avg and by Lowest Concentration of a Drug During Dosing Interval (Cmin) Following Q12H Dosing
RatioBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
IQ Cmin11.0 ± 351097.5 ± 38267.2 ± 5434.54 ± 21600
IQ Css,avg29.7 ± 4040327 ± 454252 ± 78915.4 ± 14900
SecondaryInhibitory Quotient (IQ) of BMS-626529 by Css,Avg and by Lowest Concentration of a Drug During Dosing Interval (Cmin) Following QHS Dosing

Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measures were used in evaluating IQ: Cmin and Css,avg. Geometric mean and geometric coefficient of variation are presented.

Time frame:
Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Day 2: pre-evening dose, 12,16 hours; Day 9: pre-dose, 12,16 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-evening dose
Reported as:
Geometric mean · Ratio
Inhibitory Quotient (IQ) of BMS-626529 by Css,Avg and by Lowest Concentration of a Drug During Dosing Interval (Cmin) Following QHS Dosing
RatioBMS-663068 1200 mg QHS + RTV 100 mg QHS
IQ Cmin3.86 ± 1070
IQ Css,avg67.8 ± 902
SecondaryInhibitory Quotient of BMS-626529 by Ctrough Following Q12H Dosing

Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measure was used in evaluating IQ: Ctrough. Geometric mean and geometric coefficient of variation are presented.

Time frame:
Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Day 9: pre-dose, 4,12 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-morning dose
Reported as:
Geometric mean · Ratio
Inhibitory Quotient of BMS-626529 by Ctrough Following Q12H Dosing
RatioBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
Inhibitory Quotient of BMS-626529 by Ctrough Following Q12H Dosing12.2 ± 2750120 ± 56887.3 ± 7634.61 ± 19000
SecondaryInhibitory Quotient of BMS-626529 by Ctrough Following QHS Dosing

Blood samples were collected at indicated time points to assess IQ of BMS-626529. Inhibitory quotient was calculated as the ratio of BMS-626529 in vivo exposure to in vitro measured protein binding adjusted EC90 (PBA-EC90). The following in vivo exposure measure was used in evaluating IQ: Ctrough. Geometric mean and geometric coefficient of variation are presented.

Time frame:
Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 2: pre-evening dose, 12,16 hours; Day 9: pre-dose, 12,16 hours; Day 10: pre-dose, 12 hours; Day 11: pre-dose; Days 5,6,7: pre-evening dose
Reported as:
Geometric mean · Ratio
Inhibitory Quotient of BMS-626529 by Ctrough Following QHS Dosing
RatioBMS-663068 1200 mg QHS + RTV 100 mg QHS
Inhibitory Quotient of BMS-626529 by Ctrough Following QHS Dosing4.77 ± 1010
SecondaryCmax of Ritonavir Following Q12H Dosing

Blood samples were collected at indicated time points to assess Cmax of ritonavir following Q12H dosing. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM), Day 8 evening dose (PM) and Day 8 morning + evening dose (AM+PM). Pharmacokinetic parameter values were derived by non-compartmental methods. PK Population was used which comprised of all participants who receive ritonavir and provided pharmacokinetic samples.

Time frame:
Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Reported as:
Geometric mean · Micrograms per milliliter (μg/mL)
Cmax of Ritonavir Following Q12H Dosing
Micrograms per milliliter (μg/mL)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAM
Day 1, n=10,10,100.330 ± 91.30.314 ± 1110.294 ± 59.6
Day 8, AM, n=9,10,101.31 ± 1011.30 ± 58.30.841 ± 44.9
Day 8, PM, n=9,10,01.24 ± 73.41.48 ± 47.7—
Day 8, AM+PM, n=9,10,101.27 ± 80.01.39 ± 50.70.841 ± 44.9
SecondaryCmax of Ritonavir Following QHS Dosing

Blood samples were collected at indicated time points to assess Cmax of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 evening dose (PM) and Day 8 morning (AM) + evening dose (PM).

Time frame:
Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Reported as:
Geometric mean · μg/mL
Cmax of Ritonavir Following QHS Dosing
μg/mLBMS-663068 1200 mg QHS + RTV 100 mg QHS
Day 1, n=100.257 ± 53.8
Day 8, PM, n=90.628 ± 56.4
Day 8, AM+PM, n=90.628 ± 56.4
SecondaryCtrough of Ritonavir Following Q12H Dosing

Blood samples were collected at indicated time points to access Ctrough of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8, Day 8 morning dose (AM) and Day 8 evening dose (PM).

Time frame:
Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours; Days 5,6,7: pre-morning dose
Reported as:
Geometric mean · Micrograms per milliliter (μg/mL)
Ctrough of Ritonavir Following Q12H Dosing
Micrograms per milliliter (μg/mL)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAM
Day 1, n=10,10,00.117 ± 90.10.131 ± 98.2—
Day 5, n=9,10,100.502 ± 84.30.554 ± 73.90.0831 ± 77.8
Day 6, n=9,10,100.526 ± 87.90.594 ± 77.00.0820 ± 77.9
Day 7, n=9,10,100.477 ± 93.50.587 ± 76.30.0860 ± 79.9
Day 8, n=9,10,100.470 ± 90.60.503 ± 73.20.0891 ± 81.7
Day 8, AM, n=9,10,100.345 ± 1050.393 ± 66.30.0912 ± 70.5
Day 8, PM, n=9,10,00.453 ± 86.20.476 ± 77.9—
SecondaryCtrough of Ritonavir Following QHS Dosing

Blood samples were collected at indicated time points to assess Ctrough of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Days 5, 6, 7, 8 and Day 8 evening dose (PM).

Time frame:
Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours; Days 5,6,7: pre-evening dose
Reported as:
Geometric mean · μg/mL
Ctrough of Ritonavir Following QHS Dosing
μg/mLBMS-663068 1200 mg QHS + RTV 100 mg QHS
Day 1, n=100.157 ± 87.0
Day 5, n=90.107 ± 69.4
Day 6, n=90.0845 ± 67.7
Day 7, n=90.0844 ± 65.0
Day 8, n=90.0808 ± 73.2
Day 8, PM, n=90.0830 ± 71.7
SecondaryAUC (Tau) of Ritonavir Following Q12H Dosing

Blood samples were collected at indicated time points to assess AUC (tau) of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1, Day 8 morning dose (AM) and Day 8 evening dose (PM).

Time frame:
Days 1, 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Reported as:
Geometric mean · Hour*micrograms per milliliter
AUC (Tau) of Ritonavir Following Q12H Dosing
Hour*micrograms per milliliterBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAM
Day 1, n=10,10,02.37 ± 99.52.05 ± 104—
Day 8, AM, n=9,10,109.43 ± 89.19.05 ± 62.86.76 ± 49.3
Day 8, PM, n=9,10,09.23 ± 77.110.4 ± 52.4—
SecondaryAUC (Tau) of Ritonavir Following QHS Dosing

Blood samples were collected at indicated time points to assess AUC (tau) of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 1 and Day 8 evening dose (PM).

Time frame:
Days 1, 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Reported as:
Geometric mean · Hour*micrograms per milliliter
AUC (Tau) of Ritonavir Following QHS Dosing
Hour*micrograms per milliliterBMS-663068 1200 mg QHS + RTV 100 mg QHS
Day 1, n=102.91 ± 80.4
Day 8 PM, n=96.13 ± 94.3
SecondaryAUC (0-24) of Ritonavir Following Q12H Dosing

Blood samples were collected at indicated time points to assess AUC (0-24) of ritonavir following Q12H dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.

Time frame:
Day 8: pre-morning dose, 1,2,3,4,5,6,8,12, 13,14,15,16,17,18,20 hours
Reported as:
Geometric mean · Hour*micrograms per milliliter
AUC (0-24) of Ritonavir Following Q12H Dosing
Hour*micrograms per milliliterBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAM
AUC (0-24) of Ritonavir Following Q12H Dosing18.9 ± 80.019.5 ± 56.66.76 ± 49.3
SecondaryAUC (0-24) of Ritonavir Following QHS Dosing

Blood samples were collected at indicated time points to assess AUC (0-24) of ritonavir following QHS dosing. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8.

Time frame:
Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Reported as:
Geometric mean · Hour*micrograms per milliliter
AUC (0-24) of Ritonavir Following QHS Dosing
Hour*micrograms per milliliterBMS-663068 1200 mg QHS + RTV 100 mg QHS
AUC (0-24) of Ritonavir Following QHS Dosing6.13 ± 94.3
SecondaryAccumulation Index of Ritonavir Following Q12H Dosing

Blood samples were collected at indicated time points to assess Accumulation Index of ritonavir following Q12H dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 morning dose (AM).

Time frame:
Day 8: pre-morning dose, 1,2,3,4,5,6,8,12 hours; Day 8: 13,14,15,16,17,18,20 hours
Reported as:
Geometric mean · Ratio of AUC
Accumulation Index of Ritonavir Following Q12H Dosing
Ratio of AUCBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAM
Accumulation Index of Ritonavir Following Q12H Dosing3.58 ± 64.04.41 ± 41.73.62 ± 39.8
SecondaryAccumulation Index of Ritonavir Following QHS Dosing

Blood samples were collected at indicated time points to assess Accumulation Index of ritonavir following QHS dosing. AI was calculated as ratio of AUC(tau) at steady-state to AUC(tau) after the first dose. Pharmacokinetic parameter values were derived by non-compartmental methods. Geometric mean and geometric coefficient of variation are presented for Day 8 evening dose (PM).

Time frame:
Day 8: pre-evening dose, 1,2,3,4,5,6,8 hours
Reported as:
Geometric mean · Ratio of AUC
Accumulation Index of Ritonavir Following QHS Dosing
Ratio of AUCBMS-663068 1200 mg QHS + RTV 100 mg QHS
Accumulation Index of Ritonavir Following QHS Dosing2.19 ± 16.2

Adverse events

Collected over Serious adverse events (SAEs) and Non-serious adverse events (Non-SAEs) were collected from the start of the study treatment up to 50 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-663068 600 mg Q12H + RTV 100 mg Q12H0/10 (0%)0/10 (0%)8/10 (80%)
BMS-663068 1200 mg QHS + RTV 100 mg QHS0/10 (0%)0/10 (0%)5/10 (50%)
BMS-663068 1200 mg Q12H + RTV 100 mg Q12H0/10 (0%)0/10 (0%)9/10 (90%)
BMS-663068 1200 mg Q12H + RTV 100 mg QAM0/10 (0%)0/10 (0%)8/10 (80%)
BMS-663068 1200 mg Q12H0/10 (0%)0/10 (0%)9/10 (90%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventBMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12H
HEADACHENervous system disorders4/103/104/103/104/10
NASOPHARYNGITISInfections and infestations1/100/103/102/100/10
MICTURITION URGENCYRenal and urinary disorders1/101/101/101/103/10
DIARRHOEAGastrointestinal disorders1/100/100/101/102/10
TOOTHACHEGastrointestinal disorders0/100/102/100/100/10
DISORIENTATIONPsychiatric disorders1/100/101/100/102/10
ERYTHEMASkin and subcutaneous tissue disorders1/100/100/102/101/10
RASHSkin and subcutaneous tissue disorders2/101/102/101/102/10
PALPITATIONSCardiac disorders1/100/100/100/100/10
EYE PRURITUSEye disorders0/100/101/100/100/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12HTotal
Mean41.3 ± 8.2940.7 ± 13.7040.7 ± 6.5338.4 ± 7.8342.7 ± 8.4240.8 ± 9.01
Sex: Female, Male
Sex: Female, Male(Participants)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12HTotal
Female111003
Male999101047
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BMS-663068 600 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg QHS + RTV 100 mg QHSBMS-663068 1200 mg Q12H + RTV 100 mg Q12HBMS-663068 1200 mg Q12H + RTV 100 mg QAMBMS-663068 1200 mg Q12HTotal
Race — White101010101050
08

Study locations

1 site
  • GSK Investigational Site
    Berlin, 13353, Germany
09

References and documents

Publications

  • Landry I, Zhu L, Abu Tarif M, Hruska M, Sadler BM, Pitsiu M, Joshi S, Hanna GJ, Lataillade M, Boulton DW, Bertz RJ. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2782-9. doi: 10.1128/AAC.02503-15. Print 2016 May. PubMed 26902761 ↗
  • Ray N, Hwang C, Healy MD, Whitcomb J, Lataillade M, Wind-Rotolo M, Krystal M, Hanna GJ. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):7-15. doi: 10.1097/QAI.0b013e31829726f3. PubMed 23614999 ↗
  • Nettles RE, Schurmann D, Zhu L, Stonier M, Huang SP, Chang I, Chien C, Krystal M, Wind-Rotolo M, Ray N, Hanna GJ, Bertz R, Grasela D. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis. 2012 Oct 1;206(7):1002-11. doi: 10.1093/infdis/jis432. Epub 2012 Aug 14. PubMed 22896665 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in Jun 2010, 7 months.

Results were first posted in Jan 2020, 9 years 6 months after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 7 months is below that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2009
First posted
Nov 9, 2009
StartActual
Nov 23, 2009
Primary completionActual
Jun 25, 2010
CompletionActual
Jun 25, 2010
Results first posted
Jan 3, 2020
Last update
Jan 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01009814
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 9, 2009
Start date
Nov 23, 2009
Primary completion
Jun 25, 2010
Completion
Jun 25, 2010
Results posted
Jan 3, 2020
Last update
Jan 3, 2020

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fostemsavir

Start the discussion